Does TRT Increase Heart Attack or Stroke Risk?

Gym culture still runs two incompatible headlines about TRT and the heart: either testosterone “causes heart attacks,” or TRAVERSE “proved TRT is heart-safe forever,” so cuff pressure, hematocrit, and lipids become optional.

Neither slogan is the evidence. In the large TRAVERSE cardiovascular-outcomes trial, testosterone-replacement therapy was noninferior to placebo for major adverse cardiac events (MACE) — cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke — in middle-aged and older hypogonadal men with preexisting cardiovascular disease or elevated risk (Lincoff et al., NEJM). In February 2025, FDA directed class-wide labeling updates that add TRAVERSE results, remove the boxed warning language about increased adverse cardiovascular outcomes, and still require honest blood-pressure warnings after ambulatory monitoring studies (FDA statement, Feb 28, 2025). Noninferiority on MACE is not a free pass on monitoring. A BP or hematocrit signal is not the same as proven excess heart attacks in the studied population.

This is a Research / Evidence Update for athletes and performance-minded men on or considering testosterone therapy. It is education for a licensed-provider conversation — not a diagnosis, not clearance for competition, and not advice to start, stop, or change any medication.

If your question is the cuff claim, use Does TRT raise blood pressure?. If the screenshot is lipids or ApoB, use Does TRT raise ApoB or worsen lipids?. If resting heart rate — not events — is the worry, use Your Resting Heart Rate Is High on TRT. This page owns the does TRT increase heart attack or stroke / MACE risk evidence question.

What Changed — and Why Athletes Care Now

Three timelines collided:

1. 2010s observational scares — reports of MI, stroke, and death around testosterone use drove FDA advisory attention and a boxed cardiovascular-risk warning era.
2. TRAVERSE (results published 2023) — a dedicated, randomized, placebo-controlled cardiovascular-outcomes trial in hypogonadal men at elevated CV risk answered a MACE noninferiority question the field had lacked.
3. FDA class-wide labeling (February 2025) — sponsors were directed to add TRAVERSE results to labels, retain age-related hypogonadism limitation-of-use language, remove boxed-warning language about increased adverse cardiovascular outcomes, and keep blood-pressure risk communication after ABPM studies showed class-wide pressure rises.

Athletes care because forum discourse still freezes on the 2014–2015 panic — or over-reads “noninferiority” as “ignore every cardiovascular lab.” Neither matches the current evidence stack.

What was thin in our library: a dedicated page whose primary purpose is heart-attack / stroke / MACE outcomes on TRT — separate from blood-pressure Myth framing and separate from ApoB / lipid causation.

Previous Understanding

Three athlete slogans dominated for years:

• Panic lore: Exogenous testosterone causes heart attacks and strokes; starting TRT is playing cardiovascular roulette.
• Immunity lore: Lifters who train hard are protected; TRAVERSE headlines mean monitoring is theater.
• Clinic shorthand: Observational signals were messy and confounded; a large outcomes trial was needed before slogans hardened into policy.

All three contain a grain of truth. Older observational analyses mixed formulations, doses, untreated hypogonadism, and baseline disease. Training fitness is not a clinical endpoint. Regulatory caution after safety signals was not invented by Reddit. None of those facts settles whether physiologic replacement, in the populations studied, increases adjudicated MACE versus placebo.

New Evidence

TRAVERSE: MACE noninferiority in high-risk hypogonadal men

TRAVERSE randomized 5,246 men aged 45–80 with symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and preexisting cardiovascular disease or multiple risk factors to daily transdermal 1.62% testosterone gel (dose-adjusted toward 350–750 ng/dL) or placebo. Mean treatment duration was about 22 months; mean follow-up about 33 months (Lincoff et al., NEJM; PubMed).

Primary cardiovascular end point: first occurrence of CV death, nonfatal MI, or nonfatal stroke.

Hazard ratio 0.96 (95% CI 0.78–1.17); P < 0.001 for noninferiority versus the pre-specified margin. Sensitivity analyses with event censoring after treatment interruption supported the same directional conclusion. Component events of the composite and a secondary composite that added coronary revascularization looked similar between groups.

Athlete reading: In this population — older hypogonadal men, many with established CV disease or high risk, on transdermal gel titrated into a physiologic window — testosterone was not worse than placebo for the primary MACE composite within the trial’s design. That is a safety noninferiority result, not a heart-health promotion claim and not a study of young blast-and-cruise stacks.

Signals that were higher on testosterone — and still matter

TRAVERSE was not a blank check. The testosterone arm showed higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism than placebo in the published report. Numerically higher venous thromboembolism (including DVT/PE framing in labeling discussions) appears in post-trial label communication. Those are not the primary MACE composite — and they are not irrelevant to athletes who already track hematocrit, travel, injury immobilization, or clotting risk factors.

Athlete reading: “MACE noninferior” and “every cardiovascular row is identical” are different sentences. Discuss VTE, arrhythmias, and kidney signals with a clinician when your history warrants it.

FDA February 2025: boxed CV-outcomes warning language removed; BP warnings stay

After reviewing TRAVERSE and required ambulatory blood-pressure studies, FDA informed testosterone sponsors of class-wide labeling changes (FDA drug safety statement):

• Add TRAVERSE results to labeling for testosterone products
• Retain limitation-of-use language for age-related hypogonadism
• Remove boxed-warning language related to increased risk of adverse cardiovascular outcomes
• Keep blood-pressure risk communication — ABPM programs showed class-wide pressure increases across routes

Athlete reading: Regulatory framing moved closer to “TRAVERSE did not show excess MACE in the studied hypogonadal population” while refusing to treat blood pressure as optional. That matches how our library already separates the BP claim from event-rate questions.

How this sits next to lipids and hematocrit — without collapsing topics

TRAVERSE answered a clinical event question. It was not an ApoB-optimization trial and not a hematocrit-titration study. Measuring ApoB when particle burden matters, watching hematocrit on TRT, and logging home blood pressure remain complementary jobs — not contradictions of noninferiority.

So the coherent model is:

What the Evidence Does Not Establish

TRAVERSE and the 2025 labeling update do not prove:

• That every man on any testosterone product has zero cardiovascular risk change
• That young athletes on supraphysiologic doses, oral AAS, or polypharmacy stacks inherit TRAVERSE’s MACE result
• That atrial fibrillation, VTE/PE, or AKI signals can be ignored because the primary composite met noninferiority
• That blood pressure, hematocrit, sleep apnea, and lipids stop mattering
• That age-related low T without an established hypogonadism workup is now an unrestricted indication
• That Anabolic Insights — or any article — can clear you for therapy, competition, or medication changes

It also does not authorize DIY “cardiovascular protection stacks,” unsupervised phlebotomy protocols, or stopping prescribed heart medications because a forum summarized TRAVERSE in one sentence.

Athlete Relevance

Hard-training men usually meet this question in three ways:

1. Family or personal CV history — a parent’s MI becomes the veto on starting clinician-directed TRT, or the excuse to skip monitoring after starting
2. Forum screenshot warfare — one camp cites 2014 observational panic; the other pastes “TRAVERSE = safe” and deletes the BP/hematocrit appendix
3. Mixed exposure honesty — blast-and-cruise logs get labeled “TRT” when outcomes data studied physiologic gel in older hypogonadal men

Useful companions when a clinician reviews cardiovascular risk next to testosterone therapy:

For a men’s panel that already includes advanced cardiac markers such as ApoB, see Performance Metrics Men's Edition or Elite Metrics Men's Edition. For a hormone-forward baseline with lipids in the mix, see Vital Metrics Men's Edition. Ongoing protocol checks often use the Monitoring Panel. Soft product context only — ordering labs is not a cardiovascular clearance.

Practical Implications

1. Do not treat “TRT causes heart attacks” as settled physics. TRAVERSE’s primary MACE result was noninferior to placebo in the studied population.
2. Do not treat noninferiority as “monitoring is optional.” FDA kept blood-pressure warnings; hematocrit, lipids/ApoB, and sleep remain clinician-relevant.
3. Match the evidence to the exposure. Physiologic replacement in hypogonadal men ≠ oral AAS or unsupervised supraphysiologic stacks.
4. Keep medication and eligibility decisions inside licensed care. Testosterone is prescribed only when clinically appropriate. This page does not pick your therapy.
5. Bring the full packet to the visit — event history, cuff averages, CBC, lipids/ApoB, and symptoms — instead of a single viral headline.

Questions Still Unanswered

• How do modern injectable regimens in resistance-trained men under 45 compare to TRAVERSE’s gel-treated, older, high-CV-risk cohort on adjudicated MACE?
• How should clinicians weight the AF / VTE / AKI signals next to MACE noninferiority for men with clotting history or heavy hematocrit rises?
• What is the long-term event story beyond TRAVERSE’s follow-up window when therapy continues for many years?
• How much of residual athlete CV risk on TRT is androgen exposure vs sleep apnea, stimulant use, body-mass change, and untreated lipids?

Until those answers are cleaner, the honest frame is population- and formulation-specific — not “TRT causes heart attacks,” and not “the heart question is closed so stop measuring.”

Bottom Line

For the question athletes actually type — does TRT increase heart attack or stroke risk? — the strongest dedicated outcomes evidence we have is TRAVERSE: testosterone gel was noninferior to placebo for MACE in middle-aged and older hypogonadal men with elevated cardiovascular risk. FDA’s 2025 labeling update reflects that MACE result while keeping blood-pressure warnings and retaining limits around age-related hypogonadism use. Noninferiority is not a monitoring vacation. Blood pressure, hematocrit, lipids/ApoB, sleep, and clotting history still belong in a licensed clinician’s plan — especially if your real-world exposure looks nothing like the trial.

FAQs

Does TRT cause heart attacks? TRAVERSE did not show an increase in the primary MACE composite (CV death, nonfatal MI, nonfatal stroke) versus placebo in its studied hypogonadal population. That is not the same as proving zero cardiovascular risk for every man on every regimen.

Did the FDA say testosterone is heart-safe? FDA directed class-wide updates to add TRAVERSE results and remove boxed-warning language about increased adverse cardiovascular outcomes, while keeping blood-pressure warnings after ABPM studies. Read both halves.

Does TRAVERSE apply to bodybuilding doses? Not as a free transfer. The trial studied dose-adjusted transdermal gel aiming for a physiologic range in older hypogonadal men — not supraphysiologic injectables, oral AAS, or polypharmacy stacks.

If MACE was noninferior, why monitor hematocrit and blood pressure? Because those are separate safety lanes with their own evidence and labeling. Event noninferiority does not erase erythrocytosis or ABPM pressure signals.

What labs support a cardiovascular conversation on TRT? Discuss CBC (hematocrit/hemoglobin), blood-pressure logs, a lipid panel with ApoB when particle burden matters, and any markers your clinician already uses for sleep apnea or clotting risk. Men’s panels that include advanced cardiac markers are a starting point — not a substitute for medical evaluation.